

2013 Annual Hospital-Acquired Condition Rate and Estimates of Cost Savings and Deaths Averted From 2010 to 2013

Agency for Healthcare Research and Quality
540 Gaither Road
Rockville, MD 20850
www.ahrq.gov

AHRQ Publication No. 16-0006-EF
October 2015



This document is in the public domain and may be reproduced without permission. Citation of the source is appreciated.

Suggested Citation

2013 Annual Hospital-Acquired Condition Rate and Estimates of Cost Savings and Deaths Averted From 2010 to 2013. Rockville, MD: Agency for Healthcare Research and Quality; October 2015. AHRQ Publication No. 16-0006-EF. <http://www.ahrq.gov/professionals/quality-patient-safety/pfp/index.html>

2013 Annual Hospital-Acquired Condition Rate and Estimates of Cost Savings and Deaths Averted From 2010 to 2013

Summary

Final estimates for 2013 show a further 9 percent decline in the rate of hospital-acquired conditions (HACs) from 2012 to 2013, and a 17 percent decline, from 145 to 121 HACs per 1,000 discharges, from 2010 to 2013. A cumulative total of 1.3 million fewer HACs were experienced by hospital patients over the 3 years (2011, 2012, 2013) relative to the number of HACs that would have occurred if rates had remained steady at the 2010 level. We estimate that approximately 50,000 fewer patients died in the hospital as a result of the reduction in HACs, and approximately \$12 billion in health care costs were saved from 2010 to 2013.

Although the precise causes of the decline in patient harm are not fully understood, the increase in safety has occurred during a period of concerted attention by hospitals throughout the country to reduce adverse events, spurred in part by Medicare payment incentives and catalyzed by the U.S. Department of Health and Human Services (HHS) Partnership for Patients initiative led by the Centers for Medicare & Medicaid Services (CMS).

Introduction

Much attention has been focused on preventing patient harm since the Institute of Medicine's (IOM's) 1999 publication of *To Err Is Human: Building a Safer Health System* and its subsequent 2001 publication of *Crossing the Quality Chasm: A New Health System for the 21st Century*. These reports, and others that followed, helped to shine a spotlight on patient safety but also highlighted the fact that making progress to reduce patient harm would be difficult. This attention also prompted an increase in research funding and associated activities in an effort to better understand and address this national problem.

Important principles highlighted by the IOM and leaders in the field established a foundation on which to develop approaches to improve patient safety. Among those principles was an awareness that many threats to patient safety originate in bad systems, not bad people. Patients and their skilled providers find themselves in systems that do not always take into account the factors and challenges presented by the complexities of modern health care. Persistent support for research focused on understanding health care harm—why it occurs, what can be done to prevent it, and how to spread and implement proven practices on a national scale—seems to be making a difference.

Through the aligned efforts of various organizations—including the U.S. Department of Health and Human Services' Agency for Healthcare Research and Quality (AHRQ), Centers for Disease Control and Prevention (CDC), and Centers for Medicare & Medicaid Services (CMS), along with public-private collaboratives such as the Partnership for Patients (PfP)—significant progress has been made to reduce certain HACs. Some HACs have declined dramatically in the Nation's

hospitals. For example, according to CDC's March 2014 *Healthcare-Associated Infections Progress Report*,¹ central line-associated bloodstream infections (CLABSIs) dropped 44 percent from 2008 to 2012, and some surgical site infections (SSIs) dropped as much as 20 percent. Similar results on CLABSIs have also been documented in AHRQ's nationwide Comprehensive Unit-based Safety Program (CUSP) to prevent CLABSI.²

In 2010 an HHS Office of the Inspector General (OIG) team identified the rate of harm—that is, injuries to patients associated with their care—among hospitalized Medicare patients as 27 percent. Half of these inpatients experienced one or more adverse events that resulted in a prolonged hospital stay, permanent harm, a life-sustaining intervention, or death. Almost half of all events identified in the OIG report were considered preventable.³ The persistence of this challenge prompted formation of the nationwide PfP initiative, which aimed to save lives by preventing HACs and improving the transition of care from one care setting to another in order to reduce readmissions.

The Pfp is a very large national quality improvement learning collaborative with two aims: to improve safety in acute care hospitals and to improve coordination of care at discharge to prevent readmissions. The Pfp is much more than a collection of hospital engagement network (HEN) contracts. It is a public-private partnership that seeks national change by setting clear aims, aligning and engaging multiple Federal partners and programs, aligning and engaging multiple private partners and payers, and establishing a national learning network through a CMS investment in 26 HEN contractors. These contractors successfully enrolled more than 3,700 acute care hospitals in the initiative and had these hospitals engaged in achieving the aims throughout 2012, 2013, and 2014. These hospitals account for 80 percent of the Nation's acute care discharges.

Simultaneously, CMS pursued aligned changes in payment policy, a nationwide program of technical assistance aimed at improving hospital safety and care coordination through the Nation's Quality Improvement Organizations (QIOs), and a program of work through the CMS Innovation Center known as the "Community Based Care Transitions Program" (CCTP). The purpose of CCTP is to also improve care transitions from inpatient hospitals, while documenting savings to the Medicare program. All these programs were designed to work in synergy and cooperation with one another. The Pfp is a fully aligned "full-court press" to achieve two aims: 40 percent reduction in preventable harm⁴ and 20 percent reduction in 30 day readmissions.

¹ Centers for Disease Control and Prevention. 2012 National and State Healthcare-Associated Infections Progress Report. Published March 26, 2014. <http://www.cdc.gov/hai/progress-report/index.html>.

² Initial groundbreaking work was published by Pronovost, et al., in 2006 in the *New England Journal of Medicine* (full text is available online at: <http://www.nejm.org/doi/full/10.1056/NEJMoa061115#t=article>). The AHRQ final report on this work is online at <http://www.ahrq.gov/professionals/quality-patient-safety/cusp/clabsi-final/index.html>.

³ Based on information from the HHS OIG and other sources, the preventable fraction of inpatient HACs was estimated at 44 percent. This report is available online at <http://oig.hhs.gov/oei/reports/oei-06-09-00090.pdf>.

⁴ Based on the OIG report estimating that 44 percent of HACs are preventable, a 40 percent reduction in *preventable* HACs equates to an overall 17.6 percent reduction in *total* HACs. See Exhibits A2 and A4 in the Appendix for more information on estimates and projections of cost savings and deaths averted that are based on projected and measured reductions of HACs.

At the outset of the Pfp initiative, HHS agencies contributed their expertise to developing a measurement strategy by which to track national progress in patient safety—both in general and specifically related to the preventable HACs being addressed by the Pfp. In conjunction with CMS’s overall leadership of the Pfp, AHRQ has helped coordinate development and use of the national measurement strategy. The results using this national measurement strategy have been referred to as the “AHRQ National Scorecard,” which provides summary data on the national HAC rate.⁵ The results reported in this brief are based on this national measurement strategy.

Data and Methods

Estimating the Rate of Hospital-Acquired Conditions

Data on the rate of HACs comes from three sources:

- Review of approximately 18,000 to 33,000 medical records in each year, using a structured protocol and software tool, to determine whether any of 21 types of adverse events—such as adverse drug events, falls, and pressure ulcers—occurred. The medical records used for the Medicare Patient Safety Monitoring System (MPSMS) come from the CMS Inpatient Quality Reporting (IQR) Program.⁶ After the medical records are abstracted with the MPSMS software tool, the data are used to calculate 7 of 9 Pfp HACs (2 of 9 Pfp HACs are calculated differently as described below). Overall, this represents approximately 92 percent of measured HACs calculated for the Pfp. The 9 types of HACs selected for special focus (“core HACs”) by the Pfp are listed in Exhibit A1 in the Appendix, along with the MPSMS and other measures used. Ten of the MPSMS measures are used to generate the majority of HACs in the “All Other HACs” group, which was established to allow tracking of a variety of other important sources of harm to patients in addition to the 9 “core” HACs referred to above;
- Data on SSIs are generated by a special calculation performed by CDC in support of the Pfp. The data are based on 17 major surgical procedure types, composed of the 12 operations included in the Surgical Care Improvement Project, and 5 other frequent operations, such as cesarean sections. The underlying data are reported by hospitals as part of the National Healthcare Safety Network (NHSN), operated by CDC. These data on SSIs are used to calculate the HAC rates, overall, for approximately 2 percent of all measured HACs in the Pfp initiative; and

⁵ The overall national strategy for measurement activities associated with the Pfp was described recently in the *Journal of Patient Safety* (available at: http://journals.lww.com/journalpatientsafety/Abstract/2014/09000/An_Overview_of_Measurement_Activities_in_the.2.aspx). Baseline HAC data for the 2010 AHRQ National Scorecard, and for 2011 and 2012, are available online at <http://www.ahrq.gov/professionals/quality-patient-safety/pfp/pfphac.pdf> and <http://www.ahrq.gov/professionals/quality-patient-safety/pfp/hacrate2011-12.pdf>, respectively.

⁶ Information regarding the CMS IQR Program is available at <https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/HospitalRHQDAPU.html>. Information about the MPSMS sample is also described in the article “National Trends in Patient Safety for Four Common Conditions, 2005–2011,” available at <http://www.nejm.org/doi/full/10.1056/NEJMs1300991>.

- Data for obstetric adverse events come from AHRQ Patient Safety Indicators (PSIs) 18 and 19. In addition, data on four other PSIs were selected to contribute to the “All Other HACs” referred to above. These 6 PSIs are derived from Healthcare Cost and Utilization Project (HCUP) data⁷ and account for approximately 6 percent of all measured HACs in the PfP initiative.

The MPSMS data come from a system in which a sample of IQR medical records are reviewed by trained abstractors who use a structured protocol and software tool to determine whether any of 21 specific measures of adverse events occurred during the hospital stay.⁸ Inter-rater reliability is high.⁹

The methods for acquiring the IQR sample have changed little from 2010 through 2013, and the protocols for determining if specific adverse events have occurred has not changed significantly.¹⁰ The use of a consistent data source and a consistent measurement technique gives us confidence that our estimates of the change in the HAC rate from 2010 to 2013 are unbiased.¹¹ We also have a relatively large sample size.

The methods to estimate the national HAC rate are described in detail in the document “Methods Used To Estimate the Annual PfP National Hospital-Acquired Condition (HAC) Rate,” available at <http://www.ahrq.gov/professionals/quality-patient-safety/pfp/index.html>; and the 2011 and 2012 HAC data are available at <http://www.ahrq.gov/professionals/quality-patient-safety/pfp/hacrate2011-12.html>.

Estimating the Impact of HAC Reduction on Deaths Averted and Costs Saved

As described above, the analysis of the data allows us to directly measure the number of HACs, and the vast majority (>90%) of the data are gathered through review of medical records. In contrast, our estimates of deaths averted and cost savings result from computations based on

⁷ HCUP is a family of databases and related software tools and products developed through a Federal-State-industry partnership and sponsored by AHRQ. HCUP databases are derived from administrative data and contain encounter-level, clinical, and nonclinical information, including all-listed diagnoses and procedures, discharge status, patient demographics, and charges for all patients, regardless of payer (e.g., Medicare, Medicaid, private insurance, uninsured). The HCUP databases are based on the data collection efforts of organizations in participating States that maintain statewide data systems and are partners with AHRQ. <http://www.ahrq.gov/research/data/hcup/index.html>

⁸ MPSMS methods are described in a recent publication: Wang Y, Eldridge N, Metersky M, et al. National trends in patient safety for four common conditions, 2005–2011. *N Engl J Med* 2014;370:341-51. This publication and detailed appendixes are available online at: <http://www.nejm.org/doi/full/10.1056/NEJMsa1300991#t=article>.

⁹ The measured agreement rates between abstractors using the MPSMS software tool have ranged from 94 percent to 99 percent for data elements used to identify adverse events. (Source is same as above: Wang Y, Eldridge N, Metersky M, et al.)

¹⁰ The abstraction protocol used for MPSMS has only undergone minor changes since the PfP measurement plan was established, such as when updates were necessary regarding the names of medications and other minor corrections that allow abstractors to accurately answer the questions that lead to the generation of the MPSMS rates.

¹¹ The use of the “present on admission” indicator in billing data has likely changed over time, as hospitals have become more careful in documenting which conditions were present on admission in the billing data they submit to CMS and other payers. However, greater use of the “present on admission” indicator in billing data would not affect the results of the medical record review we used to estimate 92 percent of the HACs.

changes in the number of each type of HAC. The estimated cost savings and deaths averted per HAC, shown in Exhibit 1 and Exhibit A4, and used in Exhibit A2, were based on a review of available information in published peer-reviewed articles; published and internal CMS, AHRQ, and CDC reports; and other sources, in combination with expert opinion from inside and outside the team.

These cost and mortality estimates per HAC were developed in 2010 and early 2011, prior to the start of the PfP, and were based on data available to the HHS team at the time. In preparation for the analysis conducted in 2010, we identified estimates of the association of each HAC with excess mortality and with increased costs of care. Estimating the precise impact of HACs is challenging and complex due, in part, to variable severity of individual HACs, potential for interaction among different HACs and patient comorbidities, degree to which various analyses have addressed these factors, and variable methodologies that have been used to study the impact of individual HACs on excess mortality and costs.

For many HACs, the literature did not provide precise estimates of the effects of an HAC on either mortality or costs, and, for many HACs, more than one estimate was available. In these cases judgment was used to estimate the effects of an HAC on mortality and costs. Estimates of the impact from individual HACs were also considered in light of estimates of overall hospital mortality and costs, nationally, as well as aggregate mortality and excess costs due to HACs. Exhibit 1 displays the cost and mortality estimates that were used for each HAC and are based on analyses done in late 2010 and 2011.¹²

Exhibit 1. Excess Cost and Mortality Estimated in 2011 (at the Launch of Pfp), by Hospital-Acquired Condition

PfP Hospital Acquired Condition	Estimated Additional Cost* per HAC	Estimated Additional Inpatient Mortality per HAC
Adverse Drug Events	\$5,000	.020
Catheter-Associated Urinary Tract Infections	\$1,000	.023
Central Line-Associated Bloodstream Infections	\$17,000	.185
Falls	\$7,234	.055
Obstetric Adverse Events	\$3,000	.0015
Pressure Ulcers	\$17,000	.072
Surgical Site Infections	\$21,000	.028
Ventilator-Associated Pneumonia	\$21,000	.144
Postoperative Venous Thromboembolism	\$8,000	.104

¹² See Exhibit A4 in the Appendix for additional information.

As shown in the results section below, the largest effects on estimates of the deaths averted and cost savings come from declines in pressure ulcers and adverse drug events. As shown in Exhibit 1 we estimate that pressure ulcers are associated with an excess mortality rate of 72 deaths per 1,000 and excess costs of \$17,000/case, and adverse drug events (ADEs) with an excess mortality of 20 deaths per 1,000 and excess costs of \$5,000/case.

The estimated cost per pressure ulcer was based on a report for CMS by RTI international (Kandilov, et al.; the HHS team accessed a draft report in 2010-2011, and the final October 2011 report is referenced in the Appendix). RTI estimated that the difference in costs between patients with hospital-acquired Stage III and Stage IV pressure ulcers and matched patients without hospital-acquired Stage III and IV pressure ulcers, based on bivariate descriptive analysis, is \$17,286.

This estimate was derived by first identifying hospital claims paid under the inpatient prospective payment system (IPPS) and discharged in FY 2009 that had 1 of 10 selected HACs. These were considered index claims. Costs included the initial hospital stay and costs of other inpatient sites of care that occurred within 90 days of discharge. For each index HAC claim, there were five IPPS claims with the same Medicare Severity diagnosis-related group (MS- DRG), sex, race, and age that did NOT have a Stage III or IV pressure ulcer that were used as a matched control group. They then used bivariate (descriptive) and multivariate analysis to examine the differences in Medicare program costs between the two groups.

The estimate for deaths associated with pressure ulcers was based primarily on the paper by Zhan and Miller in 2003 (see reference in Appendix). Zhan and Miller estimated that excess mortality due to pressure ulcers was 72 deaths per 1,000 pressure ulcers. This estimate is based on analysis of data from HCUP identifying injuries in 7.45 million hospital discharge abstracts from 994 acute care hospitals across 28 States in 2000. Mortality for patients with pressure ulcer was compared to mortality among a matched set of patients, where patients were matched on DRG, comorbidities, age, gender, race, and hospital. References to all the documents used in these estimates and projections are provided in the Appendix.


The team also had access to MPSMS annual reports available at the time (results through CY 2009). MPSMS data provide inpatient mortality data for the patients who experienced each type of adverse event, and for patients who were exposed to risk for the event.¹³ These MPSMS mortality data were of interest even though they could not be used directly for attribution of deaths to adverse events.

¹³ For pressure ulcers and falls, 100 percent of patients are exposed to risk for the event; but for other event types, such as CLABSIs, only a fraction of patients are exposed to risk for the event. In the case of CLABSI, only patients who received a central line as part of their inpatient care are considered at risk for the event.

Results

Final estimates for 2013 show that the national HAC rate declined by 9 percent from 2012 to 2013 and was 17 percent lower in 2013 than in 2010 (see Exhibit 2). As a result of the reduction in the rate of HACs, we estimate that approximately 800,000 fewer incidents of harm occurred in 2013 than would have occurred if the rate of HACs had remained steady at the 2010 level (Exhibit 3). Cumulatively, approximately 1.3 million fewer incidents of harm occurred in 2011, 2012, and 2013 (compared to 2010), with most of the improvement occurring in 2012 and 2013. About 40 percent of this reduction is from ADEs, about 20 percent is from pressure ulcers, and about 14 percent from catheter-associated urinary tract infections (CAUTIs) (Exhibit 4). These HACs constituted about 34 percent, 27 percent, and 8 percent of the HACs measured in the 2010 baseline rate (Exhibit A2).


Exhibit 2. Annual and Cumulative Changes in HACs, 2010 to 2013*



Source: AHRQ National Scorecard Estimates from Medicare Patient Safety Monitoring System, National Healthcare Safety Network, and Healthcare Cost and Utilization Project.


Note: The 17 percent change from 2010 to 2013 is not the sum of 2 percent, 7 percent, and 9 percent due to different total HAC rates in 2010, 2011, and 2012.

Exhibit 3. Total Annual and Cumulative HAC Reductions (Compared to 2010 Baseline)




Source: AHRQ National Scorecard Estimates from Medicare Patient Safety Monitoring System, National Healthcare Safety Network, and Healthcare Cost and Utilization Project.

Exhibit 4. Change in HACs, 2011-2013 (Total = 1,317,800)




Updated 2013 estimates show that almost 35,000 fewer patients died in hospitals as a result of the decline in HACs compared to the number of deaths that would have occurred if the rate of HACs had remained steady at the 2010 level (Exhibit 5). The majority of deaths averted occurred as a result of reductions in the rates of pressure ulcers¹⁴ and ADEs, although declines in other HACs also contributed significantly to deaths averted (Exhibit 6). Estimated cumulative deaths averted from 2011 through 2013 are approximately 50,000.

Exhibit 5. Total Annual and Cumulative Deaths Averted (Compared to 2010 Baseline)



¹⁴ The number of deaths averted for any individual HAC is the product of three factors: baseline prevalence of the HAC; percentage reduction of the HAC; and attributed mortality for the HAC. For example, pressure ulcers had a high baseline prevalence, and excess mortality attributed to pressure ulcers is high compared to other HACs (see Appendix Exhibit A2). At the same time, the 20 percent reduction in pressure ulcers is similar to the 17 percent reduction in HACs overall (Appendix Exhibit A3). However, since the baseline prevalence of pressure ulcers was high, the number of deaths averted is much higher than for other HACs even though the reduction in rates of pressure ulcers is similar to the reduction in the rate of all HACs.

Exhibit 6. Estimated Deaths Averted, by Hospital-Acquired Condition (HAC), 2011-2013



Final 2013 estimates show that the decline in HACs resulted in estimated cost savings of approximately \$8 billion in 2013. Estimated cumulative savings for 2011, 2012, and 2013 are approximately \$12 billion (Exhibit 7). As was the case for the deaths averted estimates, the majority of cost savings are estimated to result from declines in pressure ulcers and ADEs (Exhibit 8).

Exhibit 7. Total Annual and Cumulative Cost Savings (Compared to 2010 Baseline)





Exhibit 8. Estimated Cost Savings, by Hospital-Acquired Condition (HAC), 2010-2013



Discussion

The estimated 17 percent reduction in HACs from 2010 to 2013 indicates that hospitals have made substantial progress in improving safety. An estimated 1.3 million fewer harms were experienced by patients from 2010 to 2013 than would have occurred if the rate of harm had remained at the 2010 level. The reasons for this progress are not fully understood. Likely contributing causes are financial incentives created by CMS and other payers' payment policies, public reporting of hospital-level results, technical assistance offered by the QIO program to hospitals, and technical assistance and catalytic efforts of the HHS PfP initiative led by CMS.¹⁵ There is still much more work to be done, even with the 17 percent decline in the HACs we have measured for the PfP since 2010. The 2013 HAC rate of 121 HACs per 1,000 discharges means that almost 10 percent¹⁶ of hospitalized patients experienced one or more of the HACs we measured. That rate is still too high.

¹⁵ The independent evaluator of the PfP has a comprehensive evaluation design in place that will work to assess the overall contribution of the PfP initiative to the improvements documented in this paper. The CMS Office of the Actuary will use this evaluation and other data to make judgments about the overall impact of the PfP model test

¹⁶ The rate of 121 HACs per 1,000 discharges does not equate to 12.1% of patients experiencing HACs because some patients experience more than one HAC during an inpatient hospital stay. Based on prior experience reviewing HAC data, the 121 HACs per 1,000 discharges are probably experienced by fewer than 100 patients among 1,000 discharges (10 percent of inpatients).

Prevention of approximately 50,000 deaths in the 2011 to 2013 period as a result of the decline in HACs, with almost 35,000 of these deaths averted in 2013 alone, is a remarkable achievement. As indicated in the results section, the estimate of deaths averted is less precise than the estimate of the size of the reduction in HAC rates. We directly estimate the size of the reduction in HAC rates but rely on analysis from other researchers of the complex relationship between HACs and mortality to extrapolate the impact of the reduction in HACs on deaths averted. These estimates used in our analysis originate from a variety of sources and methodologies. Even with the uncertainty inherent in our statistical extrapolations, it is clear that approximately 1 million Americans have avoided harm as a result of the reduction in HACs, and that tens of thousands of deaths have been averted as a result.

We estimate an associated reduction of \$12 billion in health care costs from 2011 to 2013 as a result of the reduction in HACs, with \$8 billion of those cost savings accruing in 2013 alone. As is the case for the estimate of deaths averted, there is less precision regarding the cost savings estimates than there is about the estimates of the magnitude of reduction in HACs. Even with less precision in the estimates, the potential cost savings are compelling and warrant serious attention by hospital associations, hospital systems, and executives.

Despite the tremendous progress to date in reducing HACs, much work remains to be done to ensure that the U.S. health care system is as safe as it can possibly be. HHS and other public and private partners are continuing to work to improve hospital safety. These latest data indicate that it is possible to make substantial progress in reducing virtually all types of HACs simultaneously. PfP leaders have termed this objective as achieving “Safety Across the Board” and believe it should be a national goal.

Appendix: Incidence of Hospital-Acquired Conditions in the Partnership for Patients: Estimates and Projected and Measured Impact

Exhibit A1 provides the 2013 data on HACs. The HACs that are the focus of the PfP initiative are shown, as well as the source of the data and the corresponding measures related to each HAC. The rate for 2013 is 121 HACs per 1,000 discharges, which is a 17 percent reduction from the 2010 baseline of 145 HACs per 1,000 discharges before the start of the PfP initiative.

Exhibit A1. 2013 AHRQ National Scorecard Data on HACs (Calculated August 18, 2015)

PfP Hospital-Acquired Conditions			Final 2013 PfP HACs	
Partnership for Patients Hospital-Acquired Condition	Source (& Data Year)	Measure	PfP HACs (Normalized to 32,750,000 Discharges—Based on 2010 Baseline)	PfP Measured HACs per 1,000 Discharges
ADEs	MPSMS(2013)	ADE Associated With Digoxin	8,800	0.27
	MPSMS (2013)	ADE Associated With Hypoglycemic Agents	760,000	23.3
	MPSMS (2013)	ADE Associated With IV Heparin	170,000	5.1
	MPSMS (2013)	ADE Associated With Low Molecular Weight Heparin and Factor Xa Inhibitor	240,000	7.3
	MPSMS (2013)	ADE Associated With Warfarin	140,000	4.3
	MPSMS (2013)	Total ADE (rounded sum of above 5 measures)	1,320,000	40.3
CAUTIs	MPSMS (2013)	Catheter-Associated Urinary Tract Infections	290,000	8.8
CLABSIs	MPSMS (2013)	Blood Stream Infections Associated With Central Venous Catheters	9,200	0.28
Falls	MPSMS (2013)	In-Hospital Patient Falls	240,000	7.2
Obstetric Adverse Events	PSI (2013)	OB Trauma in Vaginal Delivery With (PSI 18) and Without Instrument (PSI 19)	77,000	2.4
Pressure Ulcers	MPSMS (2013)	Hospital-Acquired Pressure Ulcers	1,060,000	32.5
Surgical Site Infections	NHSN (2013)	SSIs for 17 selected procedures	79,000	2.4
VAPs	MPSMS (2013)	Ventilator-Associated Pneumonia	37,000	1.1
VTEs	MPSMS (2013)	Postoperative Venous Thromboembolic Events	23,000	0.71

PfP Hospital-Acquired Conditions			Final 2013 PfP HACs	
Partnership for Patients Hospital-Acquired Condition	Source (& Data Year)	Measure	PfP HACs (Normalized to 32,750,000 Discharges—Based on 2010 Baseline)	PfP Measured HACs per 1,000 Discharges
All Other Hospital-Acquired Conditions	MPSMS (2013)	Femoral Artery Puncture for Catheter Angiographic Procedures	59,000	1.8
	MPSMS (2013)	Adverse Events Associated With Hip Joint Replacements	21,000	0.63
	MPSMS (2013)	Adverse Events Associated With Knee Joint Replacements	14,000	0.42
	MPSMS (2013)	Contrast Nephropathy Associated With Catheter Angiography	250,000	7.6
	MPSMS (2013)	Hospital-Acquired MRSA	11,000	0.35
	MPSMS (2013)	Hospital-Acquired VRE	10,000	0.31
	MPSMS (2013)	Hospital-Acquired Antibiotic-Associated <i>C. difficile</i>	100,000	3.1
	MPSMS (2013)	Mechanical Complications Associated With Central Venous Catheters	110,000	3.3
	MPSMS (2013)	Postoperative Cardiac Events for Cardiac and Non- cardiac Surgeries	35,000	1.1
	MPSMS (2013)	Postoperative Pneumonia	65,000	2.0
	PSI (2013)	Iatrogenic Pneumothorax (PSI 6)	12,000	0.37
	PSI (2013)	Post-Op Hemorrhage or Hematoma (PSI 9)	20,000	0.61
	PSI (2013)	Post-Op Respiratory Failure (PSI 11)	52,000	1.6
	PSI (2013)	Accidental Puncture or Laceration (PSI 15)	63,000	1.9
MPSMS (2013) & PSI (2013)	Total All Other HACs (sum of above 14 measures)	822,000	25.1	
Total 2013 PfP HACs and HACs per 1,000 discharges (rounded)			3,957,200	121

Source: AHRQ National Scorecard Estimates from Medicare Patient Safety Monitoring System, National Healthcare Safety Network, and Healthcare Cost and Utilization Project.

Exhibit A2 shows the summary results for 2010 and 2013 after measurement of HACs was implemented and measured values replaced the baseline estimates shown in Exhibit A4 for 2010. Exhibit A3 shows just the percent change in HACs from the 2010 baseline to the 2013 rate. The cost savings and death reductions estimated for 2013 in Exhibit A2 are based on the measured 2010 and 2013 HACs and the estimated rates shown in Exhibit 1 and Exhibit A4 as to the additional cost per HAC and the additional inpatient mortality per HAC. As noted in the main body of this document, the overall measurement strategy for the PFP was published in the *Journal of Patient Safety* in September 2014 (http://journals.lww.com/journalpatientsafety/Abstract/2014/09000/An_Overview_of_Measurement_Activities_in_the.2.aspx), and specific details as to how the HAC data and rates shown were acquired and calculated was posted starting in May 2014 on the AHRQ Web site; methods and 2010-2012 data are available at <http://www.ahrq.gov/professionals/quality-patient-safety/pfp/index.html#methods>.

Exhibit A2. AHRQ National Scorecard HACs for 2013 vs. 2010, and Projected 2013 Cost Savings and Reductions in Deaths Associated With HACs

	2010 Measured Baseline for HACs (rounded)	2013 Measured HACs (rounded)	Measured Reduction in HACs (2010 vs. 2013)	Percent Reduction in Measured HACs (From 2010 to 2013)	Projected Cost Savings in 2013: Based on Measured Reductions of HACs in 2013 vs. 2010, and Baseline Projections Made in 2011 on the Additional Cost per HAC	Projected Reductions in Deaths in 2013: Based on Measured Reductions of HACs in 2013 vs. 2010, and Baseline Projections Made in 2011 on the Additional Inpatient Mortality per HAC
PfP Hospital-Acquired Condition	1,621,000	1,320,000	301,000	19%	\$1,505,000,000	6,020
Adverse Drug Events						
Catheter-Associated Urinary Tract Infections	400,000	290,000	110,000	28%	\$110,000,000	2,563
Central Line-Associated Bloodstream Infections	18,000	9,200	8,800	49%	\$149,600,000	1,628
Falls	260,000	240,000	20,000	8%	\$144,680,000	1,100
Obstetric Adverse Events	82,000	77,000	5,000	6%	\$15,000,000	7
Pressure Ulcers	1,320,000	1,060,000	260,000	20%	\$4,420,000,000	18,824
Surgical Site Infections	96,000	79,000	17,000	18%	\$357,000,000	479
Ventilator-Associated Pneumonias	38,000	37,000	1,000	3%	\$21,000,000	144
(Post-op) Venous Thromboembolisms	28,000	23,000	5,000	18%	\$40,000,000	520
All Other HACs	894,000	822,000	72,000	8%	\$1,224,000,000	3,262
Totals	4,757,000	3,957,200	799,800	17%	\$7,986,280,000	34,547

Exhibit A3. Percent Reduction in AHRQ National Scorecard HACs from 2010 to 2013




Exhibit A4 contains projections of the estimated impact of the initiative that would be launched in April 2011 as the “Partnership for Patients.” Several projections were needed for each of the types of hospital-acquired conditions (HACs) that were selected for special focus. For each HAC, the incidence, preventability, cost, and additional mortality were assessed; and a goal was set as to the percentage of preventable HACs to be prevented.¹⁷ These assessments and the associated projections are provided below in Exhibit A4.

The basis of the derivation of the overall 44 percent preventability estimate (which corresponds to the previously referenced 2010 OIG estimate) is shown in the table, as is the basis for the PfP goal of a 40 percent reduction in *preventable* HACs. Also shown is the estimate that, if 44 percent were considered preventable, the overall PfP goal to prevent 40 percent of *preventable* HACs would result in reducing the *overall* rate of HACs by approximately 17 percent.

The sources of the estimates in Exhibit A4 were identified based primarily on peer-reviewed articles published through early 2011. Other sources included reports and other information from HHS and other federally sponsored programs, and expert opinions.

Complete references to the documents accessed to make these assessments and projections, organized by HAC type, are provided at the end of this document. In general, all references listed were available in early 2011, except for several documents that were available only in a draft form prior to the launch of the PfP in April 2011; in these cases the final document is listed.

¹⁷ In 2011, this work was completed using the best available information to generate 2010 incidences and other information regarding the HACs. After these estimates were made, processes were established to measure and estimate national HACs starting with a 2010 measured baseline (4,757,000 HACs). In order to produce consistent estimates of cost savings and deaths averted for 2010 to 2013, the per-HAC estimates established for the costs and deaths associated with HACs in 2011 have not been modified.

Exhibit A4. Estimates, Goals, and Projections for HACs at the Launch of PfP Initiative in 2011

PfP Hospital-Acquired Condition	Estimated U.S. National Incidence of HACs (2010)	Estimated HAC Preventability as of 2010/2011	PfP Goal at Launch of Program (Percentage of Preventable HACs)	Combined Goal for HAC Reduction (Preventability x Goal)	PfP HAC Reduction Goal (Fewer HACs in 2014* vs. 2010 Baseline)	Estimated PfP Additional Cost** per HAC	Estimated PfP Additional Inpatient Mortality per HAC	Projected PfP Cost Savings in 2014 if 2014 Goal Met	Projected Reductions in Deaths Associated With HACs in 2014 if 2014 Goal Met
Adverse Drug Events	1,900,000	50%	50%	25%	475,000	\$5,000	.020	\$2,375,000,000	9,500
Catheter-Associated Urinary Tract Infections	530,000	40%	50%	20%	106,000	\$1,000	.023	\$106,000,000	2,470
Central Line-Associated Bloodstream Infections	40,000	50%	50%	25%	10,000	\$17,000	.185	\$170,000,000	1,850
Falls	200,000	25%	50%	12.5%	25,000	\$7,234	.055	\$180,850,000	1,375
Obstetric Adverse Events	380,000	30%	50%	15%	57,000	\$3,000	.0015	\$171,000,000	84
Pressure Ulcers	250,000	50%	50%	25%	62,500	\$17,000	.072	\$1,062,500,000	4,525
Surgical Site Infections	110,000	35%	20%	7%	7,700	\$21,000	.028	\$161,700,000	217
Ventilator-Associated Pneumonias	40,000	50%	50%	25%	10,000	\$21,000	.144	\$210,000,000	1,438
(Post-op) Venous Thromboembolisms	100,000	40%	50%	20%	20,000	\$8,000	.104	\$160,000,000	2,080
All Other HACs	2,430,000	44%	25%	11%	267,300	\$17,000	.045	\$4,544,100,000	12,109
Totals	5,980,000	44.1%	39.3%	17.4%	1,040,500	NA	NA	\$9,141,150,000	35,647

* Additional costs per HAC for Falls and Pressure Ulcers were modified in 2012 from earlier higher projections. The earlier estimates had been wrongly based on the full cost of a hospital stay that included a fall or a hospital-acquired pressure ulcer, rather than on the incremental cost due to the HAC.

References (organized by type of HAC or topic addressed)

Adverse Drug Events

Aspden P, Wolcott J, Bootman JL, et al. Preventing medication errors. Washington, DC: National Academies Press; 2006. <http://www.iom.edu/Reports/2006/Preventing-Medication-Errors-Quality-Chasm-Series.aspx>

Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 1995;274:29-34. <http://www.ncbi.nlm.nih.gov/pubmed/7791255>

Bates DW, Leape LL, Cullen DJ, et al. Effect of computerized physician order entry and a team intervention on prevention of serious medication errors. JAMA 1998, 280:1311-6. <http://www.ncbi.nlm.nih.gov/pubmed/9794308>

Cohen MM, Kimmel NL, Benage MK, et al. Medication safety program reduces adverse drug events in a community hospital. Qual Saf Health Care 2005;14(3):169-74. <http://www.ncbi.nlm.nih.gov/pubmed/15933311>

Classen DC, Jaser L, Budnitz DS. Adverse drug events among hospitalized patients: epidemiology and national estimates from a new approach. Jt Comm J Qual Patient Saf 2010;36(1): 12-20, online supplements AP1-AP9. <http://www.ncbi.nlm.nih.gov/pubmed/20112660>

Classen, Jaser, reference: Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1997 Jan 22-29;277(4):301-6. <http://www.ncbi.nlm.nih.gov/pubmed/9002492>

Corrigan JM, Donaldson MS, Kohn LT, et al. To err is human: building a safer healthcare system. Washington, DC: National Academies Press; 1999. http://books.nap.edu/catalog.php?record_id=9728

Elixhauser A, Owens P. Adverse drug events in U.S. hospitals, 2004. HCUP Statistical Brief #29. Rockville, MD: Agency for Healthcare Research and Quality; April 2007. <http://www.hcup-us.ahrq.gov/reports/statbriefs/sb29.jsp>

Hicks RW, Becker SC, Cousins DD, eds. MEDMARX data report. A report on the relationship of drug names and medication errors in response to the Institute of Medicine's call for action. Rockville, MD: Center for the Advancement of Patient Safety, US Pharmacopeia; 2008.

Johnson CL, Carlson RA, Tucker CL, et al. Using BCMA software to improve patient safety in Veterans Administration Medical Centers. J Healthc Inf Manag 2003;16:46-51. <http://www.ncbi.nlm.nih.gov/pubmed/11813523>

Office of the Inspector General. Adverse events in hospitals: national incidence among Medicare beneficiaries. OEI-06-09-00090. Washington, DC: U.S. Department of Health and Human Services; November 2010. <http://oig.hhs.gov/oei/reports/oei-06-09-00090.pdf>

Pennsylvania Patient Safety Authority 2009 Annual Report. Harrisburg: Pennsylvania PSA; April 28, 2010. http://patientsafetyauthority.org/PatientSafetyAuthority/Documents/Annual_Report_2009.pdf

Poon EG, Keohane CA, Yoon CS, et al. Effect of bar-code technology on the safety of medication administration. N Engl J Med 2010;362;1698-1707. <http://www.ncbi.nlm.nih.gov/pubmed/20445181>

Catheter-Associated Urinary Tract Infections

Apisarnthanarak A, Thongphubeth K, Sirinvaravong S, et al. Effectiveness of multifaceted hospitalwide quality improvement programs featuring an intervention to remove unnecessary urinary catheters at a tertiary care center in Thailand. Infect Control Hosp Epidemiol 2007;28:791-8. <http://www.ncbi.nlm.nih.gov/pubmed/17564980>

Gould CV, Umscheid CA, Agarwal RK, et al. Guideline for prevention of catheter-associated urinary tract infections 2009. *Infect Control Hosp Epidemiol* 2010 Apr;31(4):319-26. <http://www.jstor.org/stable/10.1086/651091>

Klevens RM, Edwards JR, Richards CL, et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. *Pub Hlth Rep* 2007;122:160-6. <http://www.ncbi.nlm.nih.gov/pubmed/17357358>

Rosenthal VD, Guzman S, Safdar N. Effect of education and performance feedback on rates of catheter-associated urinary tract infection in intensive care units in Argentina. *Infect Control Hosp Epidemiol* 2004;25:47-50. <http://www.ncbi.nlm.nih.gov/pubmed/14756219>

Saint S, Kowalski CP, Forman J, et al. A multicenter qualitative study on preventing hospital-acquired urinary tract infection in U.S. hospitals. *Infect Control Hosp Epidemiol* 2008;29:333-41. <http://www.ncbi.nlm.nih.gov/pubmed/18462146>

Stephan F, Sax H, Wachsmuth M, et al. Reduction of urinary tract infection and antibiotic use after surgery: A controlled, prospective, before-after intervention study. *Clin Infect Dis* 2006;42:1544-51. <http://www.ncbi.nlm.nih.gov/pubmed/16652311>

U.S. Department of Health and Human Services. HHS Action Plan to Prevent Healthcare-Associated Infections. 2009. <http://www.hhs.gov/ash/initiatives/hai/infection.html>

Zhan C, Elixhauser A, Richards CL Jr, et al. Identification of hospital-acquired catheter-associated urinary tract infections from Medicare claims: sensitivity and positive predictive value. *Med Care* 2009 Mar;47(3):364-9. <http://www.ncbi.nlm.nih.gov/pubmed/19194330>

Central Line-Associated Bloodstream Infections

CDC Vital Signs—Central line associated blood stream infections—U.S. 2001, 2008, 2009. *MMWR* 2011 Mar 4;60(08):243-8 (e-release March 1, 2011). http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6008a4.htm?s_cid=mm6008a4_w

Klevens RM, Edwards JR, Richards CL, et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. *Pub Hlth Rep* 2007;122:160-6. <http://www.ncbi.nlm.nih.gov/pubmed/17357358>

Marschall J, Mermell LA, Classen D, et al. Strategies to prevent central line-associated bloodstream infections in acute care hospitals. *Infect Control Hosp Epidemiol* 2008;29 Suppl 1:S22-30. <http://www.ncbi.nlm.nih.gov/pubmed/18840085>

McCarthy D, Chase D. Advancing patient safety in the U.S. Department of Veterans Affairs. New York, NY: Commonwealth Fund; 2011. Pub 1477. Vol. 9. <http://www.commonwealthfund.org/publications/case-studies/2011/mar/advancing-patient-safety>

Muto C, Herbert C, Harrison E, et al. Reduction in central line-associated bloodstream infections among patients in intensive care units—Pennsylvania, April 2001–March 2005. *MMWR* 2005;54(40):1013-6. <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5440a2.htm>

O’Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. *MMWR* 2002 Aug 9;51(RR10):1-26. <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5110a1.htm>

Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. *N Engl J Med* 2006;355(26):2725-32. <http://www.ncbi.nlm.nih.gov/pubmed/17192537>

Roselle GA. VA healthcare-associated infections activities/initiatives. Slide presentation to HHS HAI Steering Committee, December 9, 2009 (unpublished), and VA “LinKS” data at: <http://www.hospitalcompare.va.gov/aspire/index.asp>.

Scott RD. The direct medical costs of healthcare-associated infections in U.S. hospitals and the benefits of prevention. Atlanta, GA: Centers for Disease Control and Prevention; March 2009. <http://stacks.cdc.gov/view/cdc/11550/>

Timsit JF, Schwebel C, Bouadma L, et al. Chlorhexidine-impregnated sponges and less frequent dressing changes for prevention of catheter-related infections in critically ill adults, a randomized controlled trial. JAMA 2009;301(12):1231-41. <http://www.ncbi.nlm.nih.gov/pubmed/19318651>

U.S. Department of Health and Human Services. National Action Plan to Prevent Healthcare-Associated Infections. 2009. <http://www.hhs.gov/ash/initiatives/hai/infection.html>

Injury From Falls

Barrett JA, Bradshaw M, Hutchinson K, et al. Reduction of falls-related injuries using a hospital inpatient falls prevention program. J Am Geriatr Soc 2004;52:1969-70. http://onlinelibrary.wiley.com/doi/10.1111/j.1532-5415.2004.52529_8.x/full

Centers for Medicare & Medicaid Services. Medicare program; proposed changes to the hospital inpatient prospective payment systems and fiscal year 2009 rates; proposed changes to disclosure of physician ownership in hospitals and physician self-referral rules; proposed collection of information regarding financial relationships between hospitals and physicians. Fed Reg 2008 Apr 30;73(84):23528-23938. <http://www.gpo.gov/fdsys/pkg/FR-2008-04-30/html/08-1135.htm>

Currie L. Fall and injury prevention (Chapter 10). In: Hughes RG, ed. Patient safety and quality: an evidence-based handbook for nurses. Rockville, MD: Agency for Healthcare Research and Quality; 2008. AHRQ Publication No. 08-0043. <http://www.ahrq.gov/qual/nursesbdbk/>

Dacenko-Grawe L, Holm K. Evidence-based practice: a falls prevention program that continues to work. Medsurg Nurs 2008 Aug;17(4):223-7, 235.

Department of Veterans Affairs, National Center for Patient Safety. Unpublished data for 2006-2008. (Indicates more than 40% of all reports of adverse events and close calls were of falls: approximately 170,000 of 390,000 reports.)

Dykes PC, Carroll DL, Hurley A, et al. Fall prevention in acute care hospitals: a randomized trial. JAMA 2010;304(17):1912-8. <http://www.ncbi.nlm.nih.gov/pubmed/21045097>

Hitcho EB, Krauss MJ, Birge S, et al. Characteristics and circumstances of falls in a hospital setting: a prospective analysis. J Gen Intern Med 2004;19:732-9. <http://www.ncbi.nlm.nih.gov/pubmed/15209586>

Inouye SK, Bogardus ST Jr, Charpentier PA, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med 1999;340:669-76. <http://www.ncbi.nlm.nih.gov/pubmed/10053175>

Inouye SK, Brown CJ, Tinetti ME. Medicare nonpayment, hospital falls, and unintended consequences. N Engl J Med 2009;360(23):2390-3. <http://www.nejm.org/doi/full/10.1056/NEJMp0900963> (Information on Hospital Elder Life Program (HELP) referred to in this article can be found at www.hospitalelderlifeprogram.org.)

Kandilov A, Dalton K, Coomer N. Analysis report: estimating the incremental costs of hospital-acquired conditions (HACS). (Prepared by RTI International under Contract No. 500-T00007.) Baltimore, MD: Centers for Medicare & Medicaid Services; 2011.

Lancaster AD, Ayers A, Belbot B, et al. Preventing falls and eliminating injury at Ascension Health. Jt Comm J Qual Patient Saf 2007 Jul;33(7):367-75. <http://www.ncbi.nlm.nih.gov/pubmed/17711138>

Mills PD, Neily J, Luan D, Using aggregate root cause analysis to reduce falls. Jt Comm J Qual Patient Saf 2005;31(1):21-31. <http://www.ncbi.nlm.nih.gov/pubmed/15691207>

Patient Safety Reporting Initiative Updates - February 2006. 2006 Issue 2. Trenton: New Jersey Department of Health and Senior Services. http://www.state.nj.us/health/ps/documents/feb2006_newsletter.pdf

Stalhandske E, Mills P, Quigley P, et al. VHA's national falls collaborative and prevention programs. In: Advances in patient safety: new directions and alternative approaches. Vol. 2. Culture and Redesign. Rockville, MD: Agency for Healthcare Research and Quality; 2008. AHRQ Publication No. 08-0034-2. <http://www.ncbi.nlm.nih.gov/books/NBK43724/>

Obstetric Adverse Events

Abuhamad A, Grobman WA. Patient safety and medical liability: current status and an agenda for the future. *Obstet Gynecol* 2010 Sep;116(3):570-7.

Agency for Healthcare Research and Quality, Healthcare Cost and Utilization Project. Nationwide Inpatient Sample. <http://www.hcup-us.ahrq.gov/nisoverview.jsp>

Janakiraman V, Ecker J. Quality in obstetric care: measuring what matters. *Obstet Gynecol* 2010 Sep;116(3):728-32. <http://www.ncbi.nlm.nih.gov/pubmed/20733459>

Mann S, Pratt S, Gluck P, et al. Assessing quality in obstetrical care: development of standardized measures. *Jt Comm J Qual Patient Saf* 2006;32:497-505. <http://www.ncbi.nlm.nih.gov/pubmed/17987873>

Mazza F, Kitchens J, Akin M, et al. The road to zero preventable birth injuries. *Jt Comm J Qual Patient Saf* 2008;34:201-5. <http://www.ncbi.nlm.nih.gov/pubmed/18468357>

Mazza F, Kitchens J, Kerr S, et al. Eliminating birth trauma at Ascencion Health. *Jt Comm J Qual Patient Saf* 2007;33:15-24. <http://www.ncbi.nlm.nih.gov/pubmed/17283938>

Osborne M, Graham J, Cowley K, et al. Because one is too many: Catholic Health Initiatives' success in reducing preventable birth injuries. *J Healthc Qual* 2010;32(4):24-30. <http://www.ncbi.nlm.nih.gov/pubmed/20618568>

Pettker CM, Thung SF, Norwitz ER, et al. Impact of a comprehensive strategy on obstetric adverse events. *Am J Obstet Gynecol* 2009;200(492):e1-8. <http://www.ncbi.nlm.nih.gov/pubmed/19249729>

Pratt SD, Mann S, Salisbury M, et al. John M. Eisenberg Patient Safety and Quality Awards. Impact of CRM-based training on obstetric outcomes and clinicians' patient safety attitudes. *Jt Comm J Qual Patient Saf* 2007 Dec;33(12):720-5.

Simpson KR, Kortz CC, Knox GE. A comprehensive perinatal patient safety program to reduce preventable adverse outcomes and costs of liability claims. *Jt Comm J Qual Patient Saf* 2009 Nov;35(11):565-74. <http://www.ncbi.nlm.nih.gov/pubmed/19947333>

The Joint Commission. Preventing maternal death. Sentinel Event Alert Issue 44; January 26, 2010. http://www.jointcommission.org/assets/1/18/SEA_44.PDF

Toward improving the outcome of pregnancy III - enhancing perinatal health through quality, safety, and performance initiatives. White Plains, NY: March of Dimes; December 2010. Financial support provided by American Academy of Pediatrics, the American College of Obstetrics and Gynecology, and the Association of Women's Health Obstetric and Neonatal Nurses. www.marchofdimes.org/materials/toward-improving-the-outcome-of-pregnancy-iii.pdf

Pressure Ulcers

Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project. Nationwide Inpatient Sample. PSI3. http://qualityindicators.ahrq.gov/Modules/PSI_TechSpec.aspx

Centers for Medicare & Medicaid Services. Medicare program: proposed changes to the hospital inpatient prospective payment systems and fiscal year 2009 rates; proposed changes to disclosure of physician ownership in hospitals and physician self-referral rules; proposed collection of information regarding financial relationships between hospitals and physicians. Fed Reg 2008 Apr 30;73(84):23528–23938. <http://www.gpo.gov/fdsys/pkg/FR-2008-04-30/html/08-1135.htm>

Gibbons W, Shanks HT, Kleinhalter P, et al. Eliminating facility-acquired pressure ulcers at Ascension Health . Jt Comm J Qual Patient Saf 2006 Sep;32(9):488-96. <http://www.ncbi.nlm.nih.gov/pubmed/17987872>

Kandilov A, Dalton K, Coomer N. Analysis report: estimating the incremental costs of hospital-acquired conditions (HACS). (Prepared by RTI International under Contract No. 500-T00007). Baltimore, MD: Centers for Medicare & Medicaid Services; 2011.

Nalezny D, et al. Improvement report on reduction of nosocomial pressure ulcers, University of Minnesota Medical Center, Fairview (Minneapolis, Minnesota). Cambridge, MA: Institute for Healthcare Improvement; 2006.

Preventing pressure ulcers in hospitals: a toolkit for improving quality of care. Rockville, MD: Agency for Healthcare Research and Quality; April 2011. AHRQ Publication No. 11-0053-EF. <http://www.ahrq.gov/professionals/systems/long-term-care/resources/pressure-ulcers/pressureulcertoolkit/index.html>

Zhan C, Miller MR. Excess length of stay, charges, and mortality attributable to medical injuries during hospitalization. JAMA 2003 Oct 8;290(14):1868-74. <http://www.ncbi.nlm.nih.gov/pubmed/14532315>

Surgical Site Infections

Darouiche RO, Wall MJ, Itani KMF, et al. Chlorhexidine–alcohol versus povidone–iodine for surgical-site antisepsis. N Engl J Med 2010; 362:18-26. <http://www.ncbi.nlm.nih.gov/pubmed/20054046>

Haynes AB, Weiser TG, Berry WR, et al. A surgical safety checklist to reduce morbidity and mortality in a global population. N Engl J Med 2009 Jan 29;360(5):491-9. <http://www.ncbi.nlm.nih.gov/pubmed/19144931>

Klevens RM, Edwards JR, Richards CL, et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Pub Hlth Rep 2007;122:160-6. <http://www.ncbi.nlm.nih.gov/pubmed/17357358>

Stulberg, J, Delaney, C, Neuhauser, et al. Adherence to Surgical Care Improvement Project measures and association with postoperative infections, JAMA 2010 Jun 23/30;303:2479-85. <http://www.ncbi.nlm.nih.gov/pubmed?term=JAMA%202010%20Stulberg%2C%20J>

U.S. Department of Health and Human Services. National Action Plan to Prevent Healthcare-Associated Infections. 2009. <http://www.hhs.gov/ash/initiatives/hai/infection.html>

Venous Thromboembolisms (post-surgery)

AHRQ Health Care Innovations Exchange. Algorithm enhances provision of preventive treatment to at-risk inpatients, reducing incidence of venous thromboembolism. <https://innovations.ahrq.gov/profiles/algorithm-enhances-provision-preventive-treatment-risk-inpatients-reducing-incidence-venous>

AHRQ. Healthcare Cost and Utilization Project. Nationwide Inpatient Sample. PSI 12. http://qualityindicators.ahrq.gov/Modules/PSI_TechSpec.aspx

Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):338S-400S. <http://www.ncbi.nlm.nih.gov/pubmed/15383478>. Also see the Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism at: <http://www.ncbi.nlm.nih.gov/books/NBK44178/>.

Heit JA, O’Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. *Arch Intern Med* 2002;162:1245-8. <http://www.ncbi.nlm.nih.gov/pubmed/12038942>

Johanson NA, Lachiewicz PF, Lieberman JR, et al. Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. *J Am Acad Orthop Surg* 2009;17:183-96. <http://www.ncbi.nlm.nih.gov/pubmed/19264711>

Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest* 2008 Jun;133(6 Suppl):454S-545S. (Erratum in *Chest* 2008 Oct; 134(4):892.) <http://www.ncbi.nlm.nih.gov/pubmed/18574272>

Kucher N, Koo S, Quiroz R, et al Electronic alerts to prevent venous thromboembolism among hospitalized patients. *N Engl J Med* 2005 Mar 10;352(10):969-77. <http://www.ncbi.nlm.nih.gov/pubmed/15758007>

Maynard G, Stein J. Preventing hospital-acquired venous thromboembolism: a guide for effective quality improvement. Prepared by the Society of Hospital Medicine. Rockville, MD: Agency for Healthcare Research and Quality; August 2008. AHRQ Publication No. 08-0075. <http://www.ahrq.gov/qual/vtguide/>

Maynard GA, Morris TA, Jenkins IH, et al. Optimizing prevention of hospital-acquired venous thromboembolism (VTE): prospective validation of a VTE risk assessment model. *J Hosp Med* 2010 Jan;5(1):10-18. <http://www.ncbi.nlm.nih.gov/pubmed/19753640>

Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. *J Manag Care Pharm* 2007 Jul-Aug;13(6):475-86. <http://www.ncbi.nlm.nih.gov/pubmed/17672809>

Tapson VF, Hyers TM, Waldo AL, et al. Antithrombotic therapy practices in US hospitals in an era of practice guidelines. *Arch Intern Med* 2005;165:1458-64. <http://www.ncbi.nlm.nih.gov/pubmed/16009860>

Ventilator-Associated Pneumonias

Berenholtz S, Pham, J, Thompson D, et al. Collaborative cohort study of an intervention to reduce ventilator-associated pneumonia in the intensive care unit. *J Infect Control Hosp Epidemiol* 2011 Apr;32(4):305-14. <http://www.ncbi.nlm.nih.gov/pubmed/21460481>

de Smet AM, Kluytmans JA, Cooper BS, et al. Decontamination of the digestive tract and oropharynx in ICU patients. *New Engl J Med* 2009;360(1):20-31. <http://www.ncbi.nlm.nih.gov/pubmed/19118302>

Klevens RM, Edwards JR, Richards CL, et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. *Public Health Rep* 2007;122:160-6. <http://www.ncbi.nlm.nih.gov/pubmed/17357358>

McCarthy D, Chase D. Advancing patient safety in the U.S. Department of Veterans Affairs. New York, NY: Commonwealth Fund; 2011. Pub 1477. Vol. 9. <http://www.commonwealthfund.org/publications/case-studies/2011/mar/advancing-patient-safety>.

Roselle GA. VA healthcare-associated infections activities/initiatives. Slide presentation to HHS HAI Steering Committee, December 9, 2009 (unpublished), and VA “LinKS” data at: <http://www.hospitalcompare.va.gov/aspire/index.asp>.

U.S. Department of Health and Human Services. National Action Plan to Prevent Healthcare-Associated Infections. 2009. <http://www.hhs.gov/ash/initiatives/hai/infection.html>

All Other HACs

de Vries EN, Ramrattan MA, Smorenburg SM, et al. The incidence and nature of in-hospital adverse events: a systematic review. *Qual Saf Health Care* 2008;17:216-23. <http://www.ncbi.nlm.nih.gov/pubmed/18519629>

Gawande A. *The checklist manifesto: how to get things right*. New York, NY: Metropolitan Books; 2010. p. 31. <http://gawande.com/the-checklist-manifesto>

Hall M, Hamilton B, Richards K, et al. Does surgical quality improve in the American College of Surgeons national Surgical Quality Improvement Program: an evaluation of participating hospitals. *Ann Surg* 2009 Sep;250(3):363-76. <http://www.ncbi.nlm.nih.gov/pubmed/19644350>

Landrigan CP, Parry GJ, Bones CB, et al. Temporal trends in rates of patient harm resulting from medical care. *N Engl J Med* 2010 Nov 25;363(22):2124-34. <http://www.ncbi.nlm.nih.gov/pubmed/21105794>

Neily J, Mills PD, Young-Xu Y, et al. Association between implementation of a medical team training program and surgical mortality. *JAMA* 2010 Oct 20;304(15):1693-700. <http://www.ncbi.nlm.nih.gov/pubmed/20959579>

Office of the Inspector General. *Adverse events in hospitals: methods for identifying events*. Washington, DC: U.S. Department of Health and Human Services; 2010. Publication No. OEI-06-08-00221. <http://oig.hhs.gov/oei/reports/oei-06-08-00221.pdf>

Office of the Inspector General. *Adverse events in hospitals: national incidence among Medicare beneficiaries*. Washington, DC: U.S. Department of Health and Human Services; 2010. Publication No. OEI-06-09-00090. <http://oig.hhs.gov/oei/reports/oei-06-09-00090.pdf>

Total HACs

AHRQ and CMS. *Medicare Patient Safety Monitoring System Annual Reports (Qualidigm): Unpublished data for 2005, 2006, and 2009*.

de Vries EN, Ramrattan MA, Smorenburg SM, et al. The incidence and nature of in-hospital adverse events: a systematic review. *Qual Saf Health Care* 2008;17:216-23. <http://www.ncbi.nlm.nih.gov/pubmed/18519629>

Hunt DR, Verzier N, Abenda S, et al. Fundamentals of Medicare safety surveillance: intent, relevance, and transparency. In: Henriksen K, Battles JB, Marks ES, et al., eds. *Advances in patient safety: from research to implementation*. Vol. 2: Concepts and Methodology. Rockville, MD: Agency for Healthcare Research and Quality; 2005. <http://www.ncbi.nlm.nih.gov/books/NBK20489/>

Office of the Inspector General. *Adverse events in hospitals: methods for identifying events*. Washington, DC: U.S. Department of Health and Human Services; 2010. Publication No. OEI-06-08-00221. <http://oig.hhs.gov/oei/reports/oei-06-08-00221.pdf>

Office of the Inspector General. *Adverse events in hospitals: national incidence among Medicare beneficiaries*. Washington, DC: U.S. Department of Health and Human Services; 2010. Publication No. OEI-06-09-00090. <http://oig.hhs.gov/oei/reports/oei-06-09-00090.pdf>